Estrella Immunopharma, Inc. (ESLAW) stock
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.03 (-28.82%)
Close on Nov 17, 2026Market cap $14.42MP/E –Yield –
Estrella Immunopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
No profit margin figures for Estrella Immunopharma
Estrella Immunopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?